CRL · Charles River Laboratories International, Inc. · Earnings Call Transcripts & Audio
$295.01
-0.95 (-0.32%)
At close · Sep 30
Return incl. dividend (before tax)
Market Cap
$14.20B
Shares
47.74M
Volume · Sep 30
799.36K
Avg daily vol (3M)
922.66K
Charles River Laboratories International, Inc. Earnings Call Transcripts
Quarterly earnings calls for Charles River Laboratories International, Inc. (CRL), with available speaker-labelled transcripts, captured audio replays, call highlights, 8-K earnings releases and periodic filings. Investor days and conferences appear here too.
Revenue & result across quarters
Revenue Net income YoY up YoY down artefacts
▲10.4%
$989.16M
$96.47M
'22 Q3
22-11-02
▲21.5%
$1.10B
$187.41M
'22 Q4
23-02-22
▲12.6%
$1.03B
$103.13M
'23 Q1
23-05-11
▲8.9%
$1.06B
$97.02M
'23 Q2
23-08-09
▲3.8%
$1.03B
$87.39M
'23 Q3
23-11-08
▼7.9%
$1.01B
$187.08M
'23 Q4
24-02-14
▼1.7%
$1.01B
$72.96M
'24 Q1
24-05-09
▼3.2%
$1.03B
$94.08M
'24 Q2
24-08-07
▼1.6%
$1.01B
$69.66M
'24 Q3
24-11-06
▼1.1%
$1.00B
−$214.50M
'24 Q4
25-02-19
▼2.7%
$984.17M
$25.47M
'25 Q1
25-05-07
▲0.6%
$1.03B
$52.33M
'25 Q2
25-08-06
▼0.5%
$1.00B
$54.42M
'25 Q3
25-11-05
▼0.8%
$994.23M
−$276.56M
'25 Q4
26-02-18
▲1.2%
$995.83M
−$14.84M
'26 Q1
26-05-07
LATEST
▼2.7%
$1.00B
−$1.48M
'26 Q2
26-08-05
Earnings call
FY26 · Q2
2026-08-05
Charles River Laboratories International, Inc. (CRL) Q2 2026 Earnings Call Transcript
Confident tone
Biopharmaceutical demand recovery and DSA segment strength
Margin expansion and operating leverage
Non-human primate supply and NHP cost benefit
Revenue
$1.00B
▼ 2.7% YoY Diluted EPS
$-0.03
▼ 102.8% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-06-03
Charles River Laboratories International, Inc. (CRL) June 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-06-02
Charles River Laboratories International, Inc. (CRL) June 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q1
2026-05-07
Charles River Laboratories International, Inc. (CRL) Q1 2026 Earnings Call Transcript
Positive tone
Biotech and large pharma demand environment
Safety Assessment / DSA segment and NHP supply
Cost savings and operating efficiency
Revenue
$995.83M
▲ 1.2% YoY Diluted EPS
$-0.30
▼ 160% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2026-02-18
Charles River Laboratories International, Inc. (CRL) Q4 2025 Earnings Call Transcript
Balanced tone
CEO Transition and Leadership Change
NHP Supply Chain and KF Acquisition
2026 Guidance and Organic Growth Outlook
Revenue
$994.23M*
▼ 0.8% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-11-05
Charles River Laboratories International, Inc. (CRL) Q3 2025 Earnings Call Transcript
Balanced tone
Biotech funding environment
Segment performance trends
Large pharma / global biopharma client spend
Revenue
$1.00B
▼ 0.5% YoY Diluted EPS
$1.10
▼ 17.3% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-08-06
Charles River Laboratories International, Inc. (CRL) Q2 2025 Earnings Call Transcript
Positive tone
DSA demand stabilization and bookings
Raised full-year financial guidance
FX, tax legislation, and merit increase headwinds
Revenue
$1.03B
▲ 0.6% YoY Diluted EPS
$1.06
▼ 39.1% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-07
Charles River Laboratories International, Inc. (CRL) Q1 2025 Earnings Call Transcript
Balanced tone
FDA NAMs Announcement and Alternative Methods
Biotech Demand Environment
Patient Safety and Scientific Validation
Revenue
$984.17M
▼ 2.7% YoY Diluted EPS
$0.50
▼ 61.5% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-02-19
Charles River Laboratories International, Inc. (CRL) Q4 2024 Earnings Call Transcript
Cautious tone
DSA segment weakness and pricing pressure
Manufacturing Solutions (RMS) margin expansion
Biotech and global biopharma client demand
Revenue
$1.00B*
▼ 1.1% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-11-06
Charles River Laboratories International, Inc. (CRL) Q3 2024 Earnings Call Transcript
Cautious tone
DSA and Safety Assessment outlook
Footprint optimization and site consolidation
Restructuring and cost savings
Revenue
$1.01B
▼ 1.6% YoY Diluted EPS
$1.33
▼ 21.3% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-07
Charles River Laboratories International, Inc. (CRL) Q2 2024 Earnings Call Transcript
Cautious tone
DSA demand deterioration
RMS segment outlook
Biotech client trends
Revenue
$1.03B
▼ 3.2% YoY Diluted EPS
$1.74
▼ 7.9% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-05-09
Charles River Laboratories International, Inc. (CRL) Q1 2024 Earnings Call Transcript
Balanced tone
Manufacturing and RMS segment strength
Demand stabilization and recovery outlook
DSA segment performance and order trends
Revenue
$1.01B
▼ 1.7% YoY Diluted EPS
$1.30
▼ 35.3% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-02-14
Charles River Laboratories International, Inc. (CRL) Q4 2023 Earnings Call Transcript
Balanced tone
NHP supply mitigation
Demand stabilization outlook
DSA / Safety Assessment headwinds
Revenue
$1.01B*
▼ 7.9% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-11-08
Charles River Laboratories International, Inc. (CRL) Q3 2023 Earnings Call Transcript
Revenue
$1.03B
▲ 3.8% YoY Diluted EPS
$1.69
▼ 10.1% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-09
Charles River Laboratories International, Inc. (CRL) Q2 2023 Earnings Call Transcript
Revenue
$1.06B
▲ 8.9% YoY Diluted EPS
$1.89
▼ 11.3% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-05-11
Charles River Laboratories International, Inc. (CRL) Q1 2023 Earnings Call Transcript
Revenue
$1.03B
▲ 12.6% YoY Diluted EPS
$2.01
▲ 11% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-02-22
Charles River Laboratories International, Inc. (CRL) Q4 2022 Earnings Call Transcript
Revenue
$1.10B*
▲ 21.5% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-11-02
Charles River Laboratories International, Inc. (CRL) Q3 2022 Earnings Call Transcript
Revenue
$989.16M
▲ 10.4% YoY Diluted EPS
$1.88
▼ 6.5% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-08-03
Charles River Laboratories International, Inc. (CRL) Q2 2022 Earnings Call Transcript
Revenue
$973.13M
▲ 6.4% YoY Diluted EPS
$2.13
▲ 23.8% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-05-04
Charles River Laboratories International, Inc. (CRL) Q1 2022 Earnings Call Transcript
Revenue
$913.93M
▲ 10.8% YoY Diluted EPS
$1.81
▲ 50.8% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-02-16
Charles River Laboratories International, Inc. (CRL) Q4 2021 Earnings Call Transcript
Revenue
$905.05M*
▲ 14.4% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-11-03
Charles River Laboratories International, Inc. (CRL) Q3 2021 Earnings Call Transcript
Revenue
$895.94M
▲ 20.5% YoY Diluted EPS
$2.01
▼ 1% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2021-08-04
Charles River Laboratories International, Inc. (CRL) Q2 2021 Earnings Call Transcript
Revenue
$914.61M
▲ 34% YoY Diluted EPS
$1.72
▲ 28.4% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q1
2021-05-04
Charles River Laboratories International, Inc. (CRL) Q1 2021 Earnings Call Transcript
Revenue
$824.57M
▲ 16.6% YoY Diluted EPS
$1.20
▲ 17.6% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q4
2021-02-17
Charles River Laboratories International, Inc. (CRL) Q4 2020 Earnings Call Transcript
Revenue
$790.99M
▲ 14.4% YoY Diluted EPS
$2.81
▲ 74.5% YoY Gross margin
37.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY20 · Q3
2020-10-29
Charles River Laboratories International, Inc. (CRL) Q3 2020 Earnings Call Transcript
Revenue
$743.30M
▲ 11.3% YoY Diluted EPS
$2.03
▲ 39% YoY Gross margin
38.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q2
2020-08-05
Charles River Laboratories International, Inc. (CRL) Q2 2020 Earnings Call Transcript
Revenue
$682.58M
▲ 3.8% YoY Diluted EPS
$1.34
▲ 52.3% YoY Gross margin
34.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q1
2020-05-07
Charles River Laboratories International, Inc. (CRL) Q1 2020 Earnings Call Transcript
Revenue
$707.06M
▲ 17% YoY Diluted EPS
$1.02
▼ 8.1% YoY Gross margin
35.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY19 · Q4
2020-02-11
Charles River Laboratories International, Inc. (CRL) Q4 2019 Earnings Call
Revenue
$691.14M
▲ 14.9% YoY Diluted EPS
$1.61
▲ 33.1% YoY Gross margin
38.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Showing 1–29 of 29 earnings calls
Key facts
CIK
1100682
CUSIP
159864107
13F (30d)
14 filings
12 filers
Visit website
Investor relations